Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
ECSIT is a critical limiting factor for cardiac function
Linan Xu, … , David J. Grieve, Paul N. Moynagh
Linan Xu, … , David J. Grieve, Paul N. Moynagh
Published May 25, 2021
Citation Information: JCI Insight. 2021;6(12):e142801. https://doi.org/10.1172/jci.insight.142801.
View: Text | PDF
Research Article Cardiology Metabolism

ECSIT is a critical limiting factor for cardiac function

  • Text
  • PDF
Abstract

Evolutionarily conserved signaling intermediate in Toll pathways (ECSIT) is a protein with roles in early development, activation of the transcription factor NF-κB, and production of mitochondrial reactive oxygen species (mROS) that facilitates clearance of intracellular bacteria like Salmonella. ECSIT is also an important assembly factor for mitochondrial complex I. Unlike the murine form of Ecsit (mEcsit), we demonstrate here that human ECSIT (hECSIT) is highly labile. To explore whether the instability of hECSIT affects functions previously ascribed to its murine counterpart, we created a potentially novel transgenic mouse in which the murine Ecsit gene is replaced by the human ECSIT gene. The humanized mouse has low levels of hECSIT protein, in keeping with its intrinsic instability. Whereas low-level expression of hECSIT was capable of fully compensating for mEcsit in its roles in early development and activation of the NF-κB pathway, macrophages from humanized mice showed impaired clearance of Salmonella that was associated with reduced production of mROS. Notably, severe cardiac hypertrophy was manifested in aging humanized mice, leading to premature death. The cellular and molecular basis of this phenotype was delineated by showing that low levels of human ECSIT protein led to a marked reduction in assembly and activity of mitochondrial complex I with impaired oxidative phosphorylation and reduced production of ATP. Cardiac tissue from humanized hECSIT mice also showed reduced mitochondrial fusion and more fission but impaired clearance of fragmented mitochondria. A cardiomyocyte-intrinsic role for Ecsit in mitochondrial function and cardioprotection is also demonstrated. We also show that cardiac fibrosis and damage in humans correlated with low expression of human ECSIT. In summary, our findings identify a role for ECSIT in cardioprotection, while generating a valuable experimental model to study mitochondrial dysfunction and cardiac pathophysiology.

Authors

Linan Xu, Fiachra Humphries, Nezira Delagic, Bingwei Wang, Ashling Holland, Kevin S. Edgar, Jose R. Hombrebueno, Donna Beer Stolz, Ewa Oleszycka, Aoife M. Rodgers, Nadezhda Glezeva, Kenneth McDonald, Chris J. Watson, Mark T. Ledwidge, Rebecca J. Ingram, David J. Grieve, Paul N. Moynagh

×

Figure 6

Knockdown of hECSIT expression in cardiomyocytes impairs mitochondrial complex I activity and promotes cellular hypertrophy.

Options: View larger image (or click on image) Download as PowerPoint
Knockdown of hECSIT expression in cardiomyocytes impairs mitochondrial c...
(A) Immunoblot analysis, using anti-ECSIT and anti–β-actin antibodies, of cell lysates from AC16 cardiomyocyte cells transfected with control (Ctrl) or hECSIT-specific siRNA (40 nM). (B and C) AC16 cardiomyocytes transfected with control or hECSIT-specific siRNA and then treated with PBS or Angiotensin II (Ang II; 2 μM) for 24 hours. (B) Cells were stained for α-Actinin staining by immunofluorescence microscopy with nuclei being visualized by DAPI staining. Scale bars: 50 μm. (C) Quantification of cell surface area of AC16 cells (100 cells were measured for each treatment from 3 independent experiments). (D) Quantification of cell surface area of AC16 cells (100 cells were measured for each treatment from 2 independent experiments) transfected with control or hECSIT-specific siRNA, allowed to recover and grown for 7 days, and then treated with PBS or Angiotensin II (Ang II; 2 μM) for 24 hours. Immunoblot analysis, using anti-ECSIT, anti-NDUFS3, and anti-GAPDH antibodies, of cell lysates. (E) Isolated heart mitochondria from AC16 cells, previously transfected with control or hECSIT-specific siRNA, were subjected to BN-PAGE followed by in-gel activity assays using complex I– and complex IV–specific substrates. Complex I activity, as part of supercomplexes (SC), is shown in violet. Complex IV activity, as an individual complex or as part of supercomplex with complex III, is shown in brown. (F) Immunoblot analysis of lysates from AC16 cells, previously transfected with control or hECSIT specific siRNA, for levels of ECSIT, p62, PINK1, NDUFS3, Cox IV, Tom20, Fis1, mitofusin 1 (MFN1), mitofusin 2 (MFN2), OPA-1, and GAPDH. Data represent at least 2 biological replicates. (C and D) Data are expressed as the mean ± SD; 1-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts